Your session is about to expire
← Back to Search
This trial is testing the safety and efficacy of two immunotherapy drugs in combination with standard chemotherapy to treat metastatic triple negative breast cancer.
- Metastatic Breast Cancer, Triple Negative Breast Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You have a serious heart condition.You have had or currently have inflammation of the lungs not caused by an infection.You can't participate in this study if you've taken experimental drugs within the last month or 5 times the length of time it takes for the drug to leave your body, whichever is longer.You have a current or past history of autoimmune disease or a condition that required medication to suppress your immune system.You have received a live vaccine within the past month before starting the study drug.You have any medical or mental condition or abnormal lab result that could make participating in the trial risky or impact the accuracy of the trial results, according to the investigator's judgement.You have received any medication containing anti-CD40 antibodies or rhuFlt3L in the past.You have had another type of cancer in the past, but it was treated completely and has been gone for at least 3 years. Exceptions include skin cancers like basal or squamous cell carcinoma that were treated and are not currently active.
- Group 1: Cohort A
- Group 2: Cohort B
- Group 3: Cohort C
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any precedent studies of PLD Chemotherapy?
"Currently, there are 360 unique clinical trials being conducted with the goal of assessing PLD Chemotherapy. Of those active studies, 119 have reached Phase 3 in their trial process. While many of these investigations are situated in New York City, a total of 23596 distinct locations across the United States offer this treatment option."
How risky is the utilization of PLD Chemotherapy for individuals?
"With only limited data on its safety and efficacy, PLD Chemotherapy received a score of 1 in our estimation."
How many participants have been enrolled to this research endeavor?
"Affirmative. The clinicaltrials.gov database attests that this medical study, which was initially published on April 20th 2022, is actively enrolling patients. 45 individuals need to be recruited from one location for the trial's completion."
What pathologies has Peripheral Lymphocyte Depletion chemotherapy been found to remediate?
"PLD Chemotherapy is a viable course of treatment for lymphoma and hodgkins, in addition to carcinoma, bronchogenic, neuroblastomar lymphoma and hodgkins, in addition to carcinoma, bronchogenic, neuroblastoma (nb), and sezary syndrome."
What qualifications must potential participants possess in order to be accepted into this medical research?
"Applicants to this clinical trial must have been diagnosed with breast cancer and be between 18 and 99 years old. At present, 45 people are being accepted into the study."
Is this trial a pioneer in its respective field?
"Currently, 360 distinct clinical trials centering around PLD Chemotherapy have been conducted in 66 different nations across 1941 cities since Alfacell's original 1997 trial. Of those 679 studies conducted over the last two decades, 300 participants were involved in Phase 3 drug testing."
Is this experiment still accepting participants?
"Affirmative. Clinicaltrials.gov confirms that this clinical trial, first published on April 20th 2022, is actively searching for participants. 45 individuals must be recruited from one medical location."
Is this research effort limited to those aged 70 and under?
"Patients of any age 18 and above, yet below 99 years old are eligible to join this clinical trial."
Share this study with friends